Form D/A
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
MIRAGEN THERAPEUTICS, INC.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago
Previous Name(s)
- MIRAGEN THERAPEUTICS, INC.
- SIGNAL GENETICS, INC.
- SIGNAL GENETICS LLC
Item 2 Issuer Principal Place of Business and Contact Information
6200 LOOKOUT ROAD
BOULDER, CO 80301
Phone Number:
subscription required
Item 3. Related Persons
Name
WILLIAM S. MARSHALL
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
JASON A. LEVERONE
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
PAUL D. RUBIN
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
CHRISTOPHER BOWDEN
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JEFFREY S. HATFIELD
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
THOMAS E. HUGHES
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
KEVIN KOCH
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ARLENE M. MORRIS
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JOSEPH L. TURNER
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
BIOTECHNOLOGY
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
Amendment
Date of First Sale in this Offering:
08/06/2018
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
Yes
Item 9. Type(s) of Securities Offered
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
5000000
Total Amount Sold
1500000
Total Remaining to be Sold
3500000
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
1
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
MIRAGEN THERAPEUTICS, INC.
Issuer Signature
/S/ JASON A. LEVERONE
Signer Name
JASON A. LEVERONE
Signer Title
CFO TREASURER
Signature Date
10/31/2019